Nicola De Maria
A5024092214- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Alcohol Consumption and Health Effects
- Liver Diseases and Immunity
- Renal Transplantation Outcomes and Treatments
- Particle physics theoretical and experimental studies
- High-Energy Particle Collisions Research
- Drug-Induced Hepatotoxicity and Protection
- Cancer, Lipids, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Bladder and Urothelial Cancer Treatments
- Quantum Chromodynamics and Particle Interactions
- Nutrition and Health in Aging
- Cancer, Hypoxia, and Metabolism
- Estrogen and related hormone effects
- SARS-CoV-2 and COVID-19 Research
- Dark Matter and Cosmic Phenomena
- Urinary and Genital Oncology Studies
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 Clinical Research Studies
- Diet, Metabolism, and Disease
Azienda Ospedaliero-Universitaria di Modena
2015-2025
University of Verona
2021-2025
Azienda Ospedaliera Universitaria Integrata Verona
2021-2025
University of Modena and Reggio Emilia
2015-2024
Policlinico Tor Vergata
2024
Azienda Ospedaliera San Camillo-Forlanini
2023
NIHR Clinical Research Network
2019
Lymphatic Education & Research Network
2019
Medical University of South Carolina
2012
Casa Sollievo della Sofferenza
2010
Bleeding is a feared complication of invasive procedures in patients with cirrhosis and significant coagulopathy (as defined by routine coagulation tests) used to justify preprocedure use fresh frozen plasma (FFP) and/or platelets (PLT). Thromboelastography (TEG) provides more comprehensive global assessment than tests (international normalized ratio [INR] platelet count), its may avoid unnecessary blood product transfusion (defined this study as INR >1.8 count <50 × 10(9) /L) who will be...
The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results a genome-wide high-throughput analysis into tool that accurately predicts at presentation tumour growth and survival patients with HCC.Ultrasound surveillance identified HCC in 78 (training set) 54 (validation consecutive cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine volumes (V0 V1) calculate doubling time. Baseline-paired...
Recent reports suggested that direct acting antivirals (DAAs) might favor hepatocellular carcinoma (HCC). In study 1, we studied the proangiogenic liver microenvironment in 242 DAA-treated chronic hepatitis C patients with advanced fibrosis. Angiopoietin-2 (ANGPT2) expression was tissue (cirrhotic and/or neoplastic) from recurrent, de novo, nonrecurrent HCC, or never developing HCC. Circulating ANGPT2,vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) were also measured....
Chronic hepatitis C is the main cause of death in patients with end-stage liver disease. Prognosis depends on increase fibrosis, whose progression twice as rapid men women. Aim study was to evaluate effects reproductive stage fibrosis severity women and compare these findings age-matched men.A retrospective 710 consecutive biopsy-proven chronic conducted, using data from a clinical database two tertiary Italian care centers. Four groups served controls. Data about demographics, biochemistry,...
Abstract Non-alcoholic fatty liver disease (NAFLD) can be detected in up to 33.6% of inflammatory bowel (IBD) patients, often absence metabolic risk factors. Nevertheless, most previous studies on such issue were conducted within the IBD population only. The primary aim this study was compare clinical and features NAFLD patients with without (w/o IBD) identify specific phenotypes population. Among 223 78 younger compared 145 (w/o) IBD, less likely have altered enzymes, had lower mean body...
Background: Herpes simplex 1 co-infections in patients with COVID-19 are considered relatively uncommon; some reports on re-activations intensive-care units were published. The aim of the study was to analyze herpetic and their clinical manifestations hospitalized patients, performing HSV-1 PCR plasma twice a week. Methods: we conducted prospective, observational, single-center involving 70 consecutive severe/critical SARS-CoV-2 pneumonia tested for at Azienda Ospedaliero-Universitaria...
This study examined the association between dynamic angiopoietin-2 assessment and COVID-19 short- long-term clinical course. We included consecutive hospitalized patients from 1 February to 31 May 2020 with laboratory-confirmed 2 Italian tertiary referral centers (derivation cohort, n = 187 patients; validation 62 patients). Serum biomarker levels were measured by sandwich enzyme-linked immunosorbent assay. Lung tissue 9 was stained for angiopoietin-2, Tie2, CD68, CD34. Cox model used...
Individuals with chronic hepatitis C who are anti-HBc positive may carry an occult B virus (HBV) infection that can affect their response to antiviral therapy.In this study the prevalence of and HBV-DNA positivity was assessed in serum liver 285 HCV-RNA-positive subjects treated interferon-alpha at 5 mU/day for 12 months. The interferon (normal ALT undetectable HCV-RNA) evaluated three different endpoints: 1) after 6 months; 2) end treatment; 3) months discontinuation.Ninety individuals were...
In HCC, tumor microenvironment, heavily influenced by the underlying chronic liver disease, etiology and stage of tissue damage, affects progression determines high heterogeneity tumor. Aim this study was to identify circulating components microenvironment immune-mediated response affecting aggressiveness ensuing clinical outcome. We analyzed baseline paired HCC surrounding biopsies from a prospective cohort 132 patients at first diagnosis for immunolocalization PD-1/PD-L1, FoxP3,...
Abstract We report two fatal cases of acute liver failure secondary to herpes simplex virus 1 infection in COVID-19 patients, following tocilizumab and corticosteroid therapy. Screening for prompt recognition reactivation these undergoing immunomodulatory treatment, may have potentially relevant clinical consequences.
To the editor, Liver transplantation (LT) is only therapeutic option for both HCC and cirrhosis. Despite careful patient selection, HCC-R_LT occurs in as much 20%, often characterized by an aggressive clinical course high mortality. We therefore designed a proof-of-concept study aimed to analyze safety of combination therapy with nivolumab bevacizumab patients HCC-R_LT, whose tumor progressed most cases while on sorafenib therapy. In particular, we focused risk rejection overall survival...